BHC · Bausch Health Companies Inc.

Track BHC — free

$5.86 -0.21 (-3.46%) At close · Sep 11

Rebalance outlook locked

Market Cap

$2.19B

373.99M

Up next

Next earnings call

Oct 28, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$10.85B

Trailing 12 months

Net income (TTM)

−$1.10B

Trailing 12 months

Revenue growth YoY

+12.7%

Year over year

Operating margin

8.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

65.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$18.92B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.3%

Year over year · more shares

Price change (1Y)

-15.1%

Trailing year

Short interest

2.2%

Latest settlement · 3.0 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Buy Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +0%

above

Price vs 50-day avg +1%

above

RSI (14) 41

neutral

MACD trend Negative

52-week position 41%

mid-range

Momentum

relative strength

Weak

1-month return −8%

trailing

6-month return +17%

trailing

YTD return −16%

this year

Relative strength −1%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $6 — 200d above 50d

Institutional flow Distributing

-4% holders QoQ · +27 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.20% of float · ▼ -2.3% MoM · 3.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

224 holders — near 3-yr low, contrarian setup

Squeeze score 59

elevated · 0–100

Fundamentals

Fair

Revenue growth −10%

Y/Y

EPS growth +423%

Y/Y

Free cash flow $1.0B

Balance sheet $19.5B

net debt

Quant / Vol

risk profile

Very High

Volatility 56%

annualized · 1-yr

Max drawdown −44%

past year

ATR 5.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 29, 2026

Revenue growth vs. Prior Year · full year 2026 (BHC excl. B+L) Initiated 4% – 6%

Adj. EBITDA1 growth vs. Prior Year · full year 2026 (BHC excl. B+L) Non-GAAP Initiated 8% – 11%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+0% Bullish

Price vs 50-day avg

+1% Bullish

RSI (14)

41 Neutral

MACD trend

Negative Bearish

52-week position

41% Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $6 › 200d $6 — 200d above 50d

Institutional flow Distributing

-4% holders QoQ · +27 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.20% of float · ▼ -2.3% MoM · 3.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

224 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $4 Now $6 · 41% Range high $8

vs 200-day avg +0% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BHC Bausch Health Companies Inc. this stock	$2.19B	-15.7%	-9.8%	—	2.2%
TAK Takeda Pharmaceutical Co Ltd	$58.31B	+17.1%	—	—	0.1%
GALDY Galderma Group AG/ADR	$44.03B	-8.9%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$43.22B	+18.8%	+4.3%	60.8	3.2%
HLN Haleon plc	$40.41B	-9.1%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

224

% held: 66.9%
Net QoQ: +11.9M sh
Top holder: PAULSON & CO. INC.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

8.2M

Days to cover: 3.0d
Change: -195.9K sh

View

Short Volume

Short vol %

53%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

2.0K

Value: $12.7K
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

38.8%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Susie Lee

Amount: $1.0K–$15.0K
Traded: Aug 27, 2020

View

Financials

Revenue (FY)

$10.3B

Net income (FY): $157.0M
EPS diluted: $0.42

View

Filings

SEC Filings

Latest

10-Q

Filed: Jul 30, 2026
This year: 13

View

Proposed Sales

Value

$258.9K

Shares: 36.8K
Filed: Aug 19, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Performance

	5D	20D	120D	MTD	YTD
BHC	-13.3%	-7.6%	+17.0%	-8.0%	-15.7%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-12.2%	-5.8%	-0.9%	-7.7%	-27.8%

Key facts CIK 885590 CUSIP 071734107 13F (30d) 103 filings 101 filers Visit website Investor relations

BHC · Bausch Health Companies Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance